DNMT3A and myelodysplastic syndrome: Considering that mutations in genes related to DNA methylation (TET2, DNMT3A and IDH1/IDH2) were amongst the top 10 mutations identified in progressive MDS and that hypomethylation agents (HMAs) are widely used in treating MDS, we analyzed the clinical features of the patients harboring these mutations.